Meeting the regulatory challenges of the post-Brexit pharma landscape
In the inaugural PharmaLex Talks podcast, host Elizabeth Hunt
chats with Charley Maxwell
, Director QMC / Senior Consultant at Pharmalex about the post-Brexit Pharma landscape.
Their wide-ranging conversation covers many key issues including; the cost of Brexit to the Pharma industry so far, what have been, and what are foreseen to be the biggest challenges to come, how UK manufacturers are coping, the Northern Ireland Protocol, and more.